Clinical Report: Vinay Prasad Becomes New Director of FDA CBER

Overview

Vinay Prasad has been appointed as the new director of the FDA’s CBER, succeeding Peter Marks. Prasad, a hematologist-oncologist, is known for his advocacy for high-quality evidence and transparency in regulatory practices.

Background

The appointment of Vinay Prasad as director of the FDA's Center for Biologics Evaluation and Research (CBER) is significant as he will oversee the regulation of vaccines, gene therapies, and blood products. His previous experience and outspoken views on public health and medical regulation are noted.

Data Highlights

No numerical or trial data provided in the source material.

Key Findings

• Vinay Prasad succeeds Peter Marks as the director of FDA’s CBER.
• Prasad has authored over 500 academic articles and two books critiquing medical evidence and regulatory practices.
• He has been a vocal critic of COVID-19 vaccines for children and mask mandates.
• Andelyn Biosciences developed a novel gene therapy for a baby with an ultra-rare condition using its AAV Curator platform.
• Univercells Technologies launched a new bioprocessing system to enhance the production of viral vectors and vaccines.
• Cellipont Bioservices partnered with Optieum Biotechnologies for the cGMP manufacturing of a CAR T cell therapy targeting glioblastoma.

Clinical Implications

The advancements in gene therapy and bioprocessing technologies highlight ongoing efforts to address rare conditions and improve treatment options.

Conclusion

Vinay Prasad's appointment as director of CBER is a notable development for the FDA, particularly in the regulation of biologics and gene therapies.

Related Resources & Content

1. the medicine maker, This Week’s Biopharma News, 2025 -- Vinay Prasad is Back
2. reuters, Dr. Vinay Prasad Shakes Up FDA Leadership, 2025 -- Title
3. conexiant, Stanford Physician-Scientist Takes CDER Helm, 2025 -- Title
4. The ASCO Post, Longtime FDA Innovator Appointed as Director of CDER, 2025 -- Title
5. FDA, FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development, 2026 -- Title
6. FDA, FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies, 2024 -- Title
7. FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development | FDA
8. FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies | FDA
9. FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease | FDA